PLUS1
2.96
0.14 (4.96%)
0.14 (4.96%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.14 | 4.96% | 2.96 | 2.83 | 2.98 | 2.83 | 2.82 | 16:27:36 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.95 | 2.98 | 0.03 | 1.01% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,194 | 1,921,013 | $ 2.9336 | $ 5,635,521 | 6,858,552 | 0.261 - 3.86 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:05:22 | formt | 20,000 | $ 2.95 | USD |
CytoDyn (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.52B | 514.73M | 302.11M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 9.54M | $ - | 0.00% | - | - |
CytoDyn (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/15/2020 | 08:47 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) |
| 5/12/2020 | 06:00 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 4/30/2020 | 17:28 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
| 4/28/2020 | 17:29 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 4/27/2020 | 17:03 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 4/23/2020 | 17:08 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 4/22/2020 | 19:35 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.17 | 3.24 | 2.78 | 3.02 | 4,727,321 | -0.21 | -6.62% |
| 1 Month | 3.50 | 3.69 | 2.53 | 3.05 | 5,261,578 | -0.54 | -15.43% |
| 3 Months | 1.05 | 3.86 | 0.81 | 2.67 | 7,429,322 | 1.91 | 181.9% |
| 6 Months | 0.28 | 3.86 | 0.261 | 2.11 | 5,346,332 | 2.68 | 957.14% |
| 1 Year | 0.395 | 3.86 | 0.261 | 1.93 | 2,910,925 | 2.57 | 649.37% |
| 3 Years | 0.605 | 3.86 | 0.0552 | 1.71 | 1,164,976 | 2.36 | 389.26% |
| 5 Years | 0.945 | 3.86 | 0.0552 | 1.61 | 786,798 | 2.02 | 213.23% |
CytoDyn (QB) Description
| CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |
